ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2019
Added value of amyloid PET in individualized risk predictions for MCI patients.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Limited generalizability and high risk of bias in multivariable models predicting conversion risk from mild cognitive impairment to dementia: A systematic review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Pooled it
- Utility, Costs and Cost-Utility of Amyloid-PET in the Diagnostic Process of Memory Clinic Patients: A Trial-Based Economic Evaluation From AMYPAD-DPMS.European journal of neurology · 2025Trial
- Value of Knowing: Health-Related Behavior Changes following Amyloid PET Results Disclosure in Mild Cognitive Impairment.The journal of prevention of Alzheimer's disease · 2024Trial
- How healthy participants value additional diagnostic testing with amyloid-PET in patients diagnosed with mild cognitive impairment - a bidding game experiment.Alzheimer's research & therapy · 2023Trial
- A randomized controlled trial of amyloid positron emission tomography results disclosure in mild cognitive impairment.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Trial
- Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly.Alzheimer's research & therapy · 2025Article
- Prediction of Mild Cognitive Impairment Status: Pilot Study of Machine Learning Models Based on Longitudinal Data From Fitness Trackers.JMIR formative research · 2024Article
- Amyloid-PET imaging predicts functional decline in clinically normal individuals.Alzheimer's research & therapy · 2024Article
- Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.Brain : a journal of neurology · 2022Article
- The Relationship of Plasma Transthyretin Level with Global or Regional Amyloid Beta Burden in Subjects with Amnestic Mild Cognitive Impairment: Cross-Sectional Amyloid PET Study.Psychiatry and clinical psychopharmacology · 2022Article
- Is Amyloid Burden Measured by 18F-Flutemetamol PET Associated with Progression in Clinical Alzheimer's Disease?Journal of Alzheimer's disease : JAD · 2022Observational
- Biomarker testing in MCI patients-deciding who to test.Alzheimer's research & therapy · 2021Article
- No evidence for amyloid pathology as a key mediator of neurodegeneration post-stroke - a seven-year follow-up study.BMC neurology · 2020Article
- Long-term cost-effectiveness of a more accurate diagnostic work-up for dementia.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo construct a prognostic model based on amyloid positron emission tomography (PET) to predict clinical progression in individual patients with mild cognitive impairment (MCI).
methodsWe included 411 MCI patients from the Alzheimer's Disease Neuroimaging Initiative. Prognostic models were constructed with Cox regression with demographics, magnetic resonance imaging, and/or amyloid PET to predict progression to Alzheimer's disease dementia. The models were validated in the Amsterdam Dementia Cohort.
resultsThe combined model (Harrell's C = 0.82 [0.78-0.86]) was significantly superior to demographics (β = 0.100, DISCUSSION: The present study facilitates the interpretation of an amyloid PET result in the context of a patient's own characteristics and clinical assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.